LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

22.49 4.75

Buy Sell

Overview

Share price change

24h

Current

Min

21.29

Max

22.79

Key metrics
By Trading Economics
Income	202M 274M
Sales	5.4M 284M
P/E Sector Avg	9.565 49.8
Profit margin	96.33
Employees	796
EBITDA	-21M 26M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+51.12% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-385M 3.8B
Previous open	17.74
Previous close	22.49

News Sentiment

By Acuity

47%

53%

155 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

14.845 / N/A Support & Resistance

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 May 2026, 23:58 UTC

Earnings

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 May 2026, 22:57 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 May 2026, 23:52 UTC

Earnings

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 May 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 May 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 May 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 May 2026, 23:11 UTC

Earnings

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 May 2026, 23:06 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 May 2026, 23:05 UTC

Earnings

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 May 2026, 23:04 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 May 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 May 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 May 2026, 23:02 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 May 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 May 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 May 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 May 2026, 22:42 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 May 2026, 22:33 UTC

Earnings

Acquisitions, Mergers, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 May 2026, 22:32 UTC

Earnings

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 May 2026, 22:31 UTC

Earnings

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 May 2026, 22:31 UTC

Earnings

Macquarie: 68% of FY Income From International >MQG.AU

7 May 2026, 22:30 UTC

Earnings

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 May 2026, 22:30 UTC

Earnings

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 May 2026, 22:29 UTC

Earnings

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 May 2026, 22:28 UTC

Earnings

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 May 2026, 22:28 UTC

Earnings

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 May 2026, 22:27 UTC

Earnings

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 May 2026, 22:27 UTC

Earnings

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 May 2026, 22:26 UTC

Earnings

Macquarie to End Share Buyback Extended in November>MQG.AU

7 May 2026, 22:25 UTC

Earnings

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

51.12% upside

12 Months Forecast

Average 32.46 USD 51.12%

High 38 USD

Low 24 USD

Based on 14 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

14.845 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

155 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.